ARQ Wealth Advisors LLC Takes $938,000 Position in VanEck Pharmaceutical ETF $PPH

ARQ Wealth Advisors LLC purchased a new position in VanEck Pharmaceutical ETF (NASDAQ:PPH) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 9,030 shares of the company’s stock, valued at approximately $938,000. ARQ Wealth Advisors LLC owned 0.09% of VanEck Pharmaceutical ETF as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in PPH. Royal Bank of Canada grew its position in VanEck Pharmaceutical ETF by 53.3% in the 1st quarter. Royal Bank of Canada now owns 67,596 shares of the company’s stock worth $6,160,000 after purchasing an additional 23,491 shares during the period. NewEdge Advisors LLC grew its stake in shares of VanEck Pharmaceutical ETF by 7.3% during the 1st quarter. NewEdge Advisors LLC now owns 8,873 shares of the company’s stock valued at $809,000 after purchasing an additional 607 shares during the period. Qube Research & Technologies Ltd increased its position in shares of VanEck Pharmaceutical ETF by 13,856.9% during the 2nd quarter. Qube Research & Technologies Ltd now owns 16,190 shares of the company’s stock valued at $1,424,000 after purchasing an additional 16,074 shares during the last quarter. Raymond James Financial Inc. increased its position in shares of VanEck Pharmaceutical ETF by 11.8% during the 2nd quarter. Raymond James Financial Inc. now owns 22,417 shares of the company’s stock valued at $1,972,000 after purchasing an additional 2,363 shares during the last quarter. Finally, Two Sigma Securities LLC lifted its stake in shares of VanEck Pharmaceutical ETF by 40.1% in the 2nd quarter. Two Sigma Securities LLC now owns 4,480 shares of the company’s stock worth $394,000 after purchasing an additional 1,282 shares during the period.

VanEck Pharmaceutical ETF Trading Down 0.8%

NASDAQ PPH traded down $0.83 during trading hours on Friday, hitting $108.80. 263,696 shares of the company’s stock traded hands, compared to its average volume of 335,102. VanEck Pharmaceutical ETF has a 52 week low of $81.74 and a 52 week high of $112.58. The firm has a market capitalization of $950.91 million, a P/E ratio of 20.21 and a beta of 0.46. The business’s fifty day moving average price is $105.00 and its two-hundred day moving average price is $105.28.

VanEck Pharmaceutical ETF Cuts Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, July 7th. Stockholders of record on Wednesday, July 1st were paid a $0.6248 dividend. This represents a $2.50 annualized dividend and a dividend yield of 2.3%. The ex-dividend date was Wednesday, July 1st.

About VanEck Pharmaceutical ETF

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.